Breast Cancer Research and Treatment

, Volume 76, Issue 2, pp 103–109 | Cite as

Aromatase and Prostaglandin Inter-Relationships in Breast Adipose Tissue: Significance for Breast Cancer Development

  • Darshini Karuppu
  • Alan Kalus
  • Evan R. Simpson
  • Colin Clyne


The role of prostaglandins in the development of breast cancer is a topic of growing interest. Stimulation of aromatase expression within the breast has been proposed as a mechanism whereby prostaglandins could influence breast cancer growth. In the present study, we show that PGE2 is a powerful stimulator of aromatase expression in human breast adipose stromal cells. Moreover, TNFα, which also stimulates aromatase expression in breast adipose stromal cells, acts to increase the secretion of PGE2 by these cells, as well as the expression of COX 2 and PGE synthase, but not that of COX 1. On the other hand, class I cytokines had no effect, either by themselves or in the presence of estradiol. These factors had little influence on secretion of 15-deoxy-Δ12,14-PGJ2, which is inhibitory of aromatase expression by breast adipose stromal cells. These results further substantiate an important role for PGE2 to stimulate estrogen biosynthesis within the local environment of the breast.

aromatase breast cancer breast mesenchymal cells prostaglandin E2 TNFα 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 299: 1247–1250, 1989Google Scholar
  2. 2.
    Thun MJ, Namboodiri MM, Heath Jr CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593–1596, 1991Google Scholar
  3. 3.
    Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Canc Inst 88: 988–993, 1996Google Scholar
  4. 4.
    Friedman GD, Ury HK: Initial screening for carcinogenicity of commonly used drugs. J Natl Canc Inst 65: 723–733, 1980Google Scholar
  5. 5.
    Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 7: 203–205, 1996Google Scholar
  6. 6.
    Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146, 1994Google Scholar
  7. 7.
    Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA: Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83: 112–120, 2000Google Scholar
  8. 8.
    Tan WC, Privett OS, Goldyne ME: Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. Canc Res 34: 3229–3231, 1974Google Scholar
  9. 9.
    Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, Zebro T: Prostaglandins and breast cancer. Lan-cet 2: 624–626, 1977Google Scholar
  10. 10.
    Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Canc Inst 64: 1061–1070, 1980Google Scholar
  11. 11.
    Schrey MP, Patel KV: Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibro-blasts. Regulation by inflammatory mediators. Br J Canc 72: 1412–1419, 1995Google Scholar
  12. 12.
    Liu XH, Rose DP: Differential expression and regulation of cyclooxygenase-1 and-2 in two human breast cancer cell lines. Canc Res 56: 5125–5127, 1996Google Scholar
  13. 13.
    Gilhooly EM, Rose DP: The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 15: 267–270, 1999Google Scholar
  14. 14.
    Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM: Cyclooxygenase-2 expression in human breast cancer. Int J Oncol 10: 503–507, 1997Google Scholar
  15. 15.
    Hwang D, Scollard D, Byrne J, Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast can-cer. J Natl Canc Inst 90: 455–460, 1998Google Scholar
  16. 16.
    Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ: Increased expression of cyclooxygenase-2 in HER-2-overexpressing human breast cancer cells. NCI 7th SPORE Investigator's WorkshopGoogle Scholar
  17. 17.
    Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AMC: Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Canc Res 59: 1572–1577, 1999Google Scholar
  18. 18.
    Noguchi M, Taniya T, Koyasaki N, Kumaki T, Miyazaki I, Mizukami Y: Effects of the prostaglandin synthetase in-hibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)-. anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high-or low-fat diet. Canc Res 51: 2683–2689, 1991Google Scholar
  19. 19.
    Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemo-prevention of breast cancer in rats by celecoxib, a cyclooxy-genase 2 inhibitor. Canc Res 60: 2101–2103, 2000Google Scholar
  20. 20.
    Zhao Y, Agarwal VR, Mendelson CR, Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE 2 via cyclic AMP, leading to activation of promoter II of the CYP19 gene. Endocrinology 137: 5739–5742, 1996Google Scholar
  21. 21.
    O'Neill JS, Elton RA, Miller WR: Aromatase activity in adipose tissue from breast quadrants: a link with tumor site. Br Med J 296: 741–743, 1988Google Scholar
  22. 22.
    Bulun SE, Price TM, Mahendroo MS, Aitken J, Simpson ER: A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77: 1622–1628, 1993Google Scholar
  23. 23.
    Purohit A, Singh A, Ghilchik MW, Reed MJ: Inhibition of tumor necrosis factor α-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxy-estradiol. Biochem Biophys Res Commun 261: 214–217, 1999Google Scholar
  24. 24.
    Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER: Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81: 3843–3849, 1996Google Scholar
  25. 25.
    Harada N, Utsume T, Takagi Y: Tissue-specific expression of the human aromatase cytochrome P450 gene by alternative use of multiple exons I and promoters, and switching of tissue-specific exons I in carcinogenesis. Proc Natl Acad Sci USA 90: 11312–11316, 1993Google Scholar
  26. 26.
    Zhou D, Zhou C, Chen S: Gene regulation studies of aro-matase expression in breast cancer and adipose stromal cells. J Steroid Biochem Mol Biol 61: 273–280, 1997Google Scholar
  27. 27.
    Harris RE, Robertson FM, Abou-Issa HM, Farrar WB, Brueggemeier R: Genetic induction and upregulation of cy-clooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer. Med Hypotheses 52: 291–292, 1999Google Scholar
  28. 28.
    Brueggemeier RW, Quinn AL, Parret ML, Joarder FS, Harris RE, Robertson FM: Correlation of aromatase and cyclooxy-genase gene expression in human breast cancer specimens. Cancer Lett 140: 27–35, 1999Google Scholar
  29. 29.
    Rubin GL, Zhao Y, Kalus AM, Simpson ER: Peroxisome proliferator-activated receptor γ ligands inhibit estrogen bio-synthesis in human breast adipose tissue: possible implications for breast cancer therapy. Canc Res 60: 1604–1608, 2000Google Scholar
  30. 30.
    Zhao Y, Nichols JE, Bulun SE, Mendelson CR, Simpson ER: Aromatase P450 gene expression in human adipose tissue: role of a Jak/STAT pathway in regulation of the adipose-specific promoter. J Biol Chem 270: 16449–16457, 1995Google Scholar
  31. 31.
    Zhao Y, Nichols JE, Valdez R, Mendelson CR, Simpson ER: Tumor necrosis factor-α stimulates aromatase gene expression in human adipose stromal cells through use of an activat-ing protein-1 binding site upstream of promoter I.4. Mol Endocrinol 10: 1350–1357, 1996Google Scholar
  32. 32.
    Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR: Aromatase expression in health and disease. Rec Prog Horm Res 52: 185–214, 1997Google Scholar
  33. 33.
    Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER: Aromatization of androstenedione by human adipose stromal cells in monolayer culture. J Clin Endocrinol Metab 53: 412–417, 1981Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Darshini Karuppu
    • 1
  • Alan Kalus
    • 2
  • Evan R. Simpson
    • 1
  • Colin Clyne
    • 1
  1. 1.Prince Henry's Institute of Medical ResearchClaytonAustralia
  2. 2.The Plastic and Aesthetic Surgery CentreWindsorAustralia

Personalised recommendations